| Literature DB >> 31411091 |
Norbert Král1, Anne-Karien M de Waard2, François G Schellevis3,4, Joke C Korevaar3, Christos Lionis5, Axel C Carlsson6,7, Anders Larrabee Sønderlund8, Jens Søndergaard8, Lars Bruun Larsen8, Monika Hollander2, Trine Thilsing8, Agapi Angelaki5, Niek J de Wit2, Bohumil Seifert1.
Abstract
Background: Selective prevention of cardiometabolic diseases (CMD)-that is, preventive measures specifically targeting the high-risk population-may represent the most effective approach for mitigating rising CMD rates.Entities:
Keywords: Selective prevention; cardiometabolic disease; consensus development; general practice; primary care
Mesh:
Year: 2019 PMID: 31411091 PMCID: PMC6713135 DOI: 10.1080/13814788.2019.1641195
Source DB: PubMed Journal: Eur J Gen Pract ISSN: 1381-4788 Impact factor: 1.904
Background of selective CMD prevention.
| No. | Statement | 1. Rating | Reformulated statements | 2. Rating | Median | Range (9-point Likert scale) |
|---|---|---|---|---|---|---|
| 1. | Prevention of cardiometabolic disease is one of the most appropriate actions against this major health problem. | Accepted | Yes | Accepted | 9 | 9 |
| 2. | Effective interventions on a population level include the creation of a healthier and affordable environment (e.g. displaying food in supermarkets) and actions targeted at promoting a healthy lifestyle (e.g. using stairs instead of elevators). | Accepted | Yes | Accepted | 9 | 6–9 |
| 3. | Selective cardiometabolic prevention targets those defined at high risk based on individual risk profile and represents an effective approach for preventing cardiometabolic diseases. | Uncertain | Yes | Accepted | 8.5 | 5–9 |
| 4. | Identifying and treating high-risk individuals using a proactive approach is more effective than case-finding alone using the whole population approach. | Accepted | Yes | Accepted | 9 | 6–9 |
| 5. | Selective cardiometabolic prevention should be a separate prevention programme not combined with other programmes (e.g., cancer prevention). | Uncertain | No | Uncertain | 5.5 | 3–9 |
| 6. | The most efficient method to perform selective cardiometabolic prevention in primary care in a systematic way is through adoption of the stepwise approach: using initial risk assessment followed by interventions if indicated. | Uncertain | Yes | Accepted | 9 | 6–9 |
| 7. | The generic step-wise approach for selective cardiometabolic prevention should be adapted nationally/regionally with respect to local conditions into national practical guidelines. | Accepted | No | Accepted | 9 | 7–9 |
| 8. | In programmes on selective cardiometabolic prevention, positive effect of worries of patients far outweighs the negative effects. | Uncertain | Yes | Accepted | 8 | 7–9 |
Organization and funding.
| No. | Statement | 1. Rating | Reformulated statements | 2. Rating | Median | Range (9-point Likert scale) |
|---|---|---|---|---|---|---|
| 9. | EU member states should have programmes that focus on selective cardiometabolic prevention. | Uncertain | Yes | Accepted | 9 | 7–9 |
| 10. | Programmes on selective cardiometabolic prevention should be mandated on a national level. | Uncertain | Yes | Accepted | 9 | 7–9 |
| 11. | Governments should be responsible for the implementation of policy on selective cardiometabolic prevention. | Uncertain | Yes | Accepted | 9 | 7–9 |
| 12. | Costs for selective cardiometabolic prevention should be allocated and protected in regular healthcare financing. | Uncertain | Yes | Accepted | 9 | 8–9 |
| 13. | Professional and scientific organizations in each EU country should be responsible for the development of the clinical practice guidelines on selective cardiometabolic prevention. | Accepted | Yes | Accepted | 8 | 7–9 |
| 14. | Selective cardiometabolic prevention should preferably be coordinated by primary care. | Uncertain | Yes | Accepted | 8 | 7–9 |
| 15. | The effectiveness of a selective prevention programme for cardiometabolic diseases heavily depends on the participation of the target group and their long-term adherence to interventions. | Accepted | No | Accepted | 9 | 7–9 |
| 16. | Selective cardiometabolic prevention programmes should first be implemented as a pilot in each respective country and then tailored to the specific contexts that apply to that country. | Uncertain | Yes | Accepted | 9 | 8–9 |
| 17. | The data on selective cardiometabolic prevention should be collected, to monitor and scientifically evaluate the programme and allow for adjustments. | Accepted | Yes | Accepted | 9 | 7–9 |
Target group and methods of identification of risk group for selective cardiometabolic prevention.
| No. | Statement | 1. Rating | Reformulated statements | 2. Rating | Median | Range (9-point Likert scale) |
|---|---|---|---|---|---|---|
| 18. | In order to efficiently identify individuals at high risk of developing cardiometabolic diseases, reliable and relevant data on individuals is required. | Accepted | Yes | Accepted | 8.5 | 5–9 |
| 19. | Patients treated for hypertension, diabetes mellitus, cardiovascular disease, chronic renal damage and/or hypercholesterolemia are by definition not a target group for selective cardiometabolic prevention. | Uncertain | Yes | Accepted | 9 | 5–9 |
| 20. | The programme should include a validated risk assessment tool for cardiometabolic diseases (CV disease, diabetes mellitus, chronic renal failure). | Uncertain | Yes | Accepted | 9 | 7–9 |
| 21. | For the initial approach to patients within selective preventive cardiometabolic diseases programmes optimal local options should be used (post, email, call, internet, direct provision at practices). | Uncertain | Yes | Accepted | 8 | 8- 9 |
| 22. | The target population for selective cardiometabolic prevention should at least include individuals aged 40–70 years old. | Uncertain | Yes | Accepted | 8 | 5–9 |
| 23. | Men and women should have the same risk assessment tool in selective cardiometabolic prevention. | Uncertain | No | Uncertain | 5 | 1–9 |
| 24. | Men and women should have the same intervention in selective cardiometabolic prevention. | Uncertain | No | Uncertain | 5.5 | 1–9 |
| 25. | Risk score measures should be validated by each country based on national statistics of cardiometabolic diseases (if available). | Uncertain | Yes | Accepted | 9 | 7–9 |
| 26. | Preventive interventions should be based on a complete risk profile. | Uncertain | No | Deleted |
Provision of selective CMD prevention in primary care.
| No. | Statement | 1. Rating | Reformulated statements | 2. Rating | Median | Range (9-point Likert scale) |
|---|---|---|---|---|---|---|
| 27. | During a consultation in primary care an individualized intervention plan should be initiated based on the individual patient’s risk profile. | Uncertain | Yes | Accepted | 9 | 7–9 |
| 28. | Each country should have training courses for primary care teams to deliver selective cardiometabolic prevention. | Accepted | Yes | Accepted | 9 | 7–9 |
| 29. | Certification and accreditation of this course could facilitate implementation of cardiometabolic prevention. | Uncertain | Yes | Accepted | 8 | 5–9 |
| 30. | Selective cardiometabolic prevention tasks should be performed by trained multidisciplinary teams in primary care. | Accepted | Yes | Accepted | 9 | 5–9 |
| 31. | For a successful implementation of sustainable nationwide selective prevention of cardiometabolic diseases support from all relevant stakeholders (i.e. national and local government, professional organizations, healthcare insurance companies and patients organizations), is essential. | Accepted | Yes | Accepted | 9 | 7–9 |
| 32. | All data on selective cardiometabolic prevention should be recorded in primary care in a structured and validated way to be available for later evaluation. | Accepted | No | Accepted | 9 | 8–9 |